MedMira Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 1/6

MedMira şirketinin toplam hissedar öz sermayesi CA$-16.9M ve toplam borcu CA$12.9M olup, bu da borç-öz sermaye oranını -76.7% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CA$6.4M ve CA$23.2M dir.

Anahtar bilgiler

-76.7%

Borç/özkaynak oranı

CA$12.94m

Borç

Faiz karşılama oranı	n/a
Nakit	CA$2.91m
Eşitlik	-CA$16.86m
Toplam yükümlülükler	CA$23.23m
Toplam varlıklar	CA$6.36m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

We Take A Look At Whether MedMira Inc.'s (CVE:MIR) CEO May Be Underpaid

Jan 29

Here's What We Think About MedMira's (CVE:MIR) CEO Pay

Jan 20

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: MIR negatif hissedar özkaynağı var; bu, kısa vadeli varlıkların kısa vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Uzun Vadeli Yükümlülükler: MIR şirketinin negatif özkaynağı bulunmaktadır; bu, kısa vadeli varlıkların uzun vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: MIR negatif hissedar özkaynağı var ki bu yüksek borç seviyesinden daha ciddi bir durumdur.

Borcun Azaltılması: MIR 'in negatif özkaynağı var, dolayısıyla borcunun zaman içinde azalıp azalmadığını kontrol etmemize gerek yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: MIR şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: MIR un, serbest nakit akışı her yıl % 20.2 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

MedMira Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 1/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

MedMira Inc. Announces Clinical Trials to Get Underway with Multiplo(R) Complete Sy Diseases (TP/nTP) Antibody Test

New major risk - Financial position

Third quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 3Q 2023)

New minor risk - Share price stability

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 2Q 2023)

New major risk - Revenue and earnings growth

U.S. FDA Approves MedMira's Advanced Reveal G4 Rapid HIV-1/2 Antibody Test

MedMira Inc., Annual General Meeting, Feb 09, 2024

Full year 2023 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in FY 2022)

Medmira Inc. Provides Update on Its Progress to Achieve Regulatory Approval in Canada and the USA for Its Infectious Disease Rapid Tests

Third quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 3Q 2022)

Second quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 2Q 2022)

MedMira Inc., Annual General Meeting, Feb 16, 2023

First quarter 2023 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 1Q 2022)

MedMira Inc. Introduces VYRA TriDemic

Full year 2022 earnings released: CA$0.003 loss per share (vs CA$0.001 loss in FY 2021)

MedMira Inc. Announces Board Changes

Third quarter 2022 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 3Q 2021)

MedMira Inc. Provides an Update on the New in Vitro Diagnostic Medical Devices Regulation in the European Market

MedMira Inc. Provides an Update on Regulatory Work for Canada for Its VYRA™ Product Line

Second quarter 2022 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 2Q 2021)

We Take A Look At Whether MedMira Inc.'s (CVE:MIR) CEO May Be Underpaid

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Medmira Inc. Announces VYRA CoV2Flu and Additional Regulatory Opportunities

MedMira Inc. announced that it has received CAD 1.665691 million in funding

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

MedMira Inc. announced that it has received CAD 0.500108 million in funding

Third quarter 2021 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 3Q 2020)

MedMira Inc. Announces Performance Update on World Health Organisation SARS-CoV2 Serology Standards

Second quarter 2021 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 2Q 2020)

MedMira Inc. Announces Expansion of its Product Portfolio and Outlines the Company’s Covid-19 Market and Regulatory Plan

MedMira Inc. Announces Progress Update on its COVID-19 Product Family

New 90-day high: CA$0.43

Here's What We Think About MedMira's (CVE:MIR) CEO Pay

Medmira Inc. Announces Product Update

MedMira Inc. Applies to US FDA to Obtain FDA Emergency Use Authorization for the REVEALCOVID-19TM Total Antibody Test

First quarter 2021 earnings released: EPS CA$0.001

New 90-day low: CA$0.23

Full year 2020 earnings released: CA$0.003 loss per share

New 90-day low: CA$0.23

MedMira Reports Additional Independent Performance Evaluation Results of REVEALCOVID-19™ Total Antibody Test

New 90-day low: CA$0.28

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin